AUSTIN, Texas, July 20, 2020 /PRNewswire/ — Luminex Corporation (NASDAQ: LMNX) today announced that the Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the company’s xMAP® SARS-CoV-2 Multi-Antigen IgG Assay. Clinical laboratories can now use this serology assay to identify the presence of antibodies in people who have been infected with the... Read more
AUSTIN, Texas, July 8, 2020 /PRNewswire/ — Luminex Corporation (Nasdaq: LMNX) today announced 2nd quarter 2020 revenues of between $109 and $110 million, up more than 30% over the 2nd quarter of 2019. Highlights include: Molecular Diagnostics revenue of approximately $65 million, up over 100% vs. Q2 2019 Sample-to-answer MDx revenue of approximately $30 million, up... Read more
AUSTIN, Texas, July 1, 2020 /PRNewswire/ — Luminex Corporation (NASDAQ: LMNX) today announced that the company has delivered the first of its new xMAP® INTELLIFLEX Systems to several of its Life Science Research Partners, achieving a major milestone in the company’s strategy to extend its xMAP Technology with new functionality to facilitate new applications. Initially intended... Read more
AUSTIN, Texas, June 29, 2020 /PRNewswire/ — Luminex Corporation (NASDAQ: LMNX) today announced that the company has submitted an Emergency Use Authorization request to the U.S. Food and Drug Administration (FDA) for its xMAP® SARS-CoV-2 Multi-Antigen IgG assay. The assay was developed to provide additional capacity to detect antibodies in patients who may have been exposed... Read more
AUSTIN, Texas, May 8, 2020 /PRNewswire/ — Luminex Corporation (NASDAQ: LMNX) (“Luminex”) announced today the pricing of its offering of $260,000,000 aggregate principal amount of 3.00% Convertible Senior Notes due 2025 (the “Convertible Notes”) in a private placement pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The delivery of... Read more
Delivers Accelerated Organic Growth and Return to Profitability AUSTIN, Texas, May 4, 2020 /PRNewswire/ — Luminex Corporation (Nasdaq: LMNX) today announced results for its first quarter ended March 31, 2020. All amounts in this release are in conformity with U.S. generally accepted accounting principles (“GAAP”). CURRENT HIGHLIGHTS Total revenue for the first quarter of $90.4M,... Read more
AUSTIN, Texas, April 22, 2020 /PRNewswire/ — Luminex Corporation (NASDAQ: LMNX) today announced that it plans to report results for the first quarter ended March 31, 2020 on Monday, May 4, 2020. A press release announcing the results is scheduled for release after the close of trading on that date. Management will hold a conference... Read more
AUSTIN, Texas, April 6, 2020 /PRNewswire/ — Luminex Corporation today announced 1st quarter 2020 revenues of just over $90 million, up approximately 10% over the 1st quarter of 2019 and approximately 8% above the top end of its previously communicated 1st quarter revenue guidance range of $82 to $84 million. Highlights include: Molecular Diagnostics Revenue of... Read more
AUSTIN, Texas, April 6, 2020 /PRNewswire/ — Luminex Corporation (NASDAQ: LMNX) today announced that the Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for its ARIES® SARS-CoV-2 Assay for rapid detection of the virus that causes COVID-19. The assay runs on the ARIES® System, an FDA-cleared, sample-to-answer, automated, on-demand molecular diagnostic platform.... Read more
AUSTIN, Texas, March 31, 2020 /PRNewswire/ — Luminex Corporation (NASDAQ: LMNX) today announced that it has received $642,450 in funding from the Biomedical Advanced Research and Development Authority (BARDA). These funds will help support development, testing, and submission later this week for an Emergency Use Authorization (EUA) for the ARIES® SARS-CoV-2 Assay. This assay will... Read more